From Petri Dish to Profit

The transition from a world-class research lab to a commercially viable business is the ultimate trial by fire for any agbiotech company. It requires a radical internal pivot from scientific experimentation to strict operational execution—and it demands an external alignment with investors who understand that biology doesn't operate on a software schedule. The panel will look past early-stage hype to analyze what the next cohort of agbiotech companies urgently needs from the broader capital base. They will discuss how to structure founder-investor partnerships that survive long-tail development cycles, the friction points of building commercial team models, and the massive financial returns available to those who play the long game.